FAGRON AND ARSEUS MEDICAL REALISE STRONG GROWTH
MANAGEMENT CONFIRMS OUTLOOK FOR 2010
Waregem (Belgium)/Rotterdam (the Netherlands)*, 16 April 2010 – In the first quarter of 2010, the consolidated turnover of Arseus increased 7.4% to € 96.8 million. Organic growth was 3.2%.
Ger van Jeveren, CEO of Arseus: “Arseus had a strong start of 2010 with turnover growth of 7.4%, of which 3.2% was organic growth. The result achieved by Arseus Medical in particular deserves a compliment. In spite of the phase out of a number of activities with low gross margins, Arseus Medical had sufficient resilience for realising an organic growth of 3.6%. The
persistently strong result achieved by Fagron is due to the successful revitalisation of pharmaceutical compounding in Europe designed to provide for the growing need for tailormade medication. Corilus in 2010 took up where it left off in 2009; with the successful rollout of its software in Europe. Arseus Dental experienced a difficult start of 2010, but achieved
good results in March. The activities in Switzerland and the activities related to dental laboratories exhibited initial signs of recovery in March. It is however still too early to say whether this represents a structural recovery.
We look to the future with confidence and consequently confirm the expectations for 2010 that we announced earlier.”
Unaudited management figures (x 1,000 euro)
Q1 2010 Q1 2009 Evolution Organic growth
Fagron 38,633 34,633 11.5% 7.6%
Arseus Dental 38,423 37,919 1.3% -0.6%
Arseus Medical 12,632 10,535 19.9% 3.6%
Corilus 7,103 7,015 1.3% 1.3%
Total 96,791 90,132 7.4% 3.2%
* This press release was sent out by Arseus NV and Arseus BV.

FAGRON
Fagron grew 11.5% in the first quarter of 2010. Organic growth was 7.6%. The excellent result is due to the successful revitalisation of pharmaceutical compounding in Europe designed to provide for the growing need for tailor-made medication. In revitalising pharmaceutical compounding, Fagron’s emphasis is on providing education about the possibilities of tailormade
compounded products to prescribers, the continuous investment in innovation and
product development and the introduction of new products and concepts for pharmaceutical compounding.

ARSEUS DENTAL
Arseus Dental grew 1.3% in the first quarter of 2010. Organic growth was -0.6%. Following a difficult start in 2010, good results were realised in March, partly supported by a number of dental fairs. The first signs of a cautious recovery in the demand for precision components for the dental orthopaedic industry and in activities related to dental laboratories were visible in March.

ARSEUS MEDICAL
Arseus Medical grew 19.9% in the first quarter of 2010. In spite of the phase out of activities with low gross margins, Arseus Medical succeeded in achieving an organic growth of 3.6%. This growth is a confirmation of Arseus Medical’s success in adding new value-added exclusive distributions and differentiating activities to its product range and in successfully introducing
these on the market.
Good progress was also made with the integration of the Belgian Duo-Med, a leading distributor of innovative and exclusive medical technologies to hospitals in the Benelux, acquired in 2009.
For example, Arseus Medical Nederland teams were trained by Duo-Med's medical specialists.
Duo-Med’s innovative medical products were increasingly introduced in the Netherlands.

CORILUS
Corilus grew 1.3% in the first quarter of 2010 in comparison to the exceptionally strong result achieved in the same period last year. In the first quarter, the Softalmo software package for ophthalmologists was successfully implemented in a second hospital in France. Contracts were
signed with two other French hospitals for the supply and installation of Softalmo. At the end of March, contracts were signed with three healthcare centres in Paris for the supply and installation of the new Julie Santé module introduced at the beginning of 2010.

ACQUISITION OF TREASURY SHARES
During the period of 2 March to 31 March, Arseus purchased 119,885 treasury shares at an average price of € 9.0873 per share. At 31 March 2010, Arseus owned 1,093,800 treasury shares. This represents 3.51% of the total number of outstanding shares.

OUTLOOK1
Based on the current view and the existing Arseus portfolio, Arseus’ management is expecting turnover growth of between 5% and 10% in 2010 and a recurring EBITDA that is expected to grow faster than turnover.

CONFERENCE CALL
Ger van Jeveren (CEO) and Jan Peeters (CFO) will provide further details on the trading update during a conference call scheduled for today. The conference call starts at 9:30 CET. You can join from 9:15 onwards by calling +31 10 713 72 95 (the Netherlands) or +32 2 404 03 34
(Belgium).
FINANCIAL CALENDAR
10 May 15:00 Annual General Meeting of Shareholders
14 July* Trading update second quarter 2010
20 August* Half-year figures for 2010
15 October* Trading update third quarter 2010
* Results and trading updates will be published at 07:30 a.m.

tijd 09.56
Arseus EUR 9,50 -3ct en 15.700 sts omzet.